Stock markets | Business Post

Meet Ray Dalio, the corporate contrarian who’s ‘shorting Europe’

The founder of Bridgewater is the archetypal hedge fund creator: white, well-educated and idiosyncratic. Right now, the firm is shorting on some of Europe’s biggest companies, among them Adidas and Siemens, Bayer, BNP Paribas and Sanofi. But why?

Business Post's View

Editorial: Rather than collapsing, the stock market is correcting to reflect normality

The post-pandemic bounce has not materialised, but the current slide in share prices is not a doomsday scenario – just a bubble bursting

Dan O’Brien: What’s causing the inflation crisis if profiteering isn’t the culprit?

Core inflation in the US, where government intervention was excessive, has been rising at twice the rate of the eurozone

Boohoo to boost executive bonuses to counter share slump

Fast-fashion firm shareholders to vote on new long-term target-bonus plan for Irish boss and other executives after five-year growth plan falls flat

Biotech veteran Friel to list Poolbeg Pharma on Nasdaq using new deals

The company raised £25 million from institutions and high net worth individuals when it floated on the London stock exchange last year

Funds sell over €30m worth of Glenveagh shares as other shareholders up stakes

Singapore’s sovereign wealth fund has boosted its stake in the listed Irish homebuilder, while a London hedge fund has reduced its holding

US hedge fund makes short bet against Irish Continental

The owner of Irish Ferries saw business and revenue pick up last year after a buffeting from Covid-19, but its shares have been on the slide since January

Smurfit gambling firm issues €1.5m incentive as stock hits all-time low

Las Vegas-based GAN has issued restricted stocks to key executives, including founder Dermot Smurfit himself

Investor Anderson grows stake in Ormonde to over 24 per cent

Veteran stock market player has boosted his influence over mining company with stake now worth just over €1 million

Weight Watchers Ireland ceases operations as parent acquires franchise

Directors of the Irish business, which had been in operation since 1986, say the Covid-19 pandemic made future uncertain

Milestone for Euronext Dublin as tech firm HealthBeacon floats

Healthbeacon is the first company to come through Euronext’s IPO Ready programme and this month aims to raise €25 million from its flotation

Vincent Boland: Time for a debate on the potentially dangerous blowback of buyback

Companies buying up their own shares is nothing new in the corporate world, and Apple is merely the latest behemoth to do it, but it remains a controversial practice

Norges Bank takes 3 per cent stake in Dalata as hotel group bounces back

The hotel group had a recent share price slump but is now benefiting from loosening of pandemic restrictions

Greencore boss Coveney offloads £1.35m of company stock

The sandwich-maker’s chief executive now holds roughly £3.5m worth of shares, at their current price of £1.35

Norwegian Air revenues down by 92% in first half of 2021

Covid-19 travel restrictions have forced restructuring at the airline

Smurfit buys $251,000 worth of shares in his online gaming firm

The chief executive now owns nearly $35 million of shares in the expanding internet gambling software and content company

Major British hedge funds bet against Greencore

The large funds’ shorting of the convenience food producer has led to speculation about a possible fall in share price, but may be part of a wider strategy

O’Driscoll’s Roaring Water takes a €130k dip into the red

The loss recorded last year contrasts with a profit of €2.1 million made the year before, and reduces accumulated profits from €10.9 million to €10.7 million

Two big to fail: will the sale of Davy undermine Irish banking?

Davy Stockbrokers is likely to be bought by Irish Life or Bank of Ireland, and with AIB buying Goodbody, it will create two banking behemoths, raising a number of questions as to what that will mean for the market here

Company Watch: Open Orphan could realise £20 million in first non-core asset IPO

Co-founder Cathal Friel has indicated that a series of spinouts could unlock £750 million for shareholders in the Dublin-based pharma company